Last reviewed · How we verify
CAIV-T 10^7
CAIV-T 10^7 is a live attenuated influenza vaccine.
CAIV-T 10^7 is a live attenuated influenza vaccine. Used for Influenza prevention.
At a glance
| Generic name | CAIV-T 10^7 |
|---|---|
| Sponsor | MedImmune LLC |
| Drug class | live attenuated vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | Phase 2 |
Mechanism of action
It works by stimulating the body's immune system to produce a protective response against influenza viruses.
Approved indications
- Influenza prevention
Common side effects
- Injection site pain
Key clinical trials
- A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children (PHASE2)
- Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older Against Culture-confirmed Influenza (PHASE3)
- Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A and B, Live Cold-adapted (CAIV-T) in Healthy Children (PHASE2)
- A Phase II, Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, CAIV-T in Healthy Children and Adolescents Ages 6 to Less Than 18 Years. (PHASE2)
- Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine (CAIV-T) in Healthy Children (PHASE2)
- Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |